Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
2 November 2023
New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this market failure, providing compensation regardless of sales volume.
An eye on sustainability at the Economist’s Future of Health Europe
30 October 2023
Learn more about how the topic of sustainability was tackled by a broad range of speakers and the key themes which emerged.
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Athanassios Vozikis and Dimitrios Kourouklis take us to Greece.
Grow and diversify funding for prevention to boost the nation’s health and prosperity, urges landmark report
12 October 2023
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
Reimagining Prevention for a Healthier, More Prosperous Society
12 October 2023
In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth.
Around The World in HTAs: The Slovak Republic – Valuing the Future
13 September 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Patricia Cubi-Molla & Jake Hitch, OHE, and Róbert Babeľa, Slovak Medical University, take us to the Slovak Republic.
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Dalia Dawoud, Pillar Pinilla-Dominguez, Caroline Bregman, and Hania El Banhawi take us to Egypt.
The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
18 July 2023
The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.
This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.